In the FIGHT trial of liraglutide in advanced HFrEF, the primary endpoint was neutral, with numerically more heart-failure events observed in the liraglutide group [46]
Butler J, Packer M, Siddiqi TJ, Bohm M, Brueckmann M, Januzzi JL, et al
Several different laboratory regulations cover the lifecycle of pharmaceutical products
Plasma exosomes contribute to microvascular damage in diabetic retinopathy by activating the classical complement pathway
More recent research published in Frontiers in Pharmacology (2021) demonstrated accelerated wound healing in animal models through increased blood flow and collagen repair
Other well-known GLP-1 agonists include Wegovy, Saxenda, and Byetta, all of which have varying uses and dosing recommendations